Interleukin-10 (IL-10) is a potent anti-inflammatory/immune cytokines markedly increased in endotoxemia. This endocytokine and has received growing attention for its theratoxin-induced TNF␣ and IL-6 up-regulation was however peutic potential. To aid therapeutic studies of IL-10 in vivo, suppressed in mice expressing IL-10 after intramuscular a replication-deficient adenoviral vector expressing mouse gene transfer. While cytokine gene expression was IL-10 was constructed and characterized. The transgene inhibited to varying degrees in different organs, a maximal protein IL-10 was shown to markedly inhibit endotoxinreduction was seen in the lung, thus also indicating the induced tumor necrosis factor ␣ (TNF␣) production by efficacy of systemic IL-10 gene product at multiple tissue mouse and rat macrophages in vitro. Intramuscular injecsites. Finally, we provided evidence that only when present tion of this vector in mice resulted in efficient expression in abnormally high concentrations in the circulation followof transgene mRNA in the muscle and active release of ILing intraperitoneal gene delivery, IL-10 by itself had someIntroduction 10 and hence may not be suitable for certain therapeutic Interleukin-10 (IL-10) is a homodimeric protein with a and toxicological studies where exaggerated and/or flexwide spectrum of anti-inflammatory/immune activities ible systemic presentation is desirable. We and others and has shown great potential to be used for treatment have recently shown that cytokine gene transfer in vivo of inflammatory or immune illnesses. 1 IL-10 inhibits cytoby adenoviral vector-based techniques is very efficient kine production and immune surface molecule and may be used to achieve transient but continuing expression by various cell types in vitro. 1 Its anticytokine expression at different tissue sites. [13] [14] [15] [16] [17] [18] [19] These inflammatory or anti-immune properties are also being features actually make adenoviral vectors an attractive intensively investigated in a number of in vivo models vehicle for IL-10 gene therapy in clinical settings of relaincluding endotoxemia, transplantation, autoimmune tively transient nature such as transplantation and diseases, immune complex-or allergen-induced lung inflammatory diseases in contrast to genetic diseases inflammation and cutaneous conditions. [2] [3] [4] [5] [6] Recently, this where the transgene product is required to be present on cytokine is also shown to have antitumor effects in vivo. 7 a long-term basis. Since the therapeutic applications of However, nearly all in vivo studies to date are carried out IL-10 have not been studied by using adenoviral vectors, by using recombinant IL-10. [2] [3] [4] [5] [6] Recombinant cytokines in the current study, we have constructed and characincluding IL-10 are known to be short-lived and have terized a replication-deficient adenoviral vector expresslimited access to the tissue interstitium in vivo. 8, 9 ing murine IL-10 and investigated the usefulness of this Recently, gene transfer technologies have been developed vector in both therapeutic and toxicological studies of ILto seek efficient and prolonged expression of cytokines 10 in vivo. in vivo. 10, 11 In this regard, plasmid-mediated IL-10 gene transfer has been used to study the therapeutic potential of this cytokine in endotoxemia.
10 (Ad5E1mIL-10) (Figure 1 ), corresponding to a 2.2 kb 10 was injected intramuscularly (i.m.) into the hind legs of Balb/c mice. The release of mIL-10 into serum was fragment of viral DNA as predicted (Figure 2a ). These results demonstrate the incorporation of mIL-10 cDNA vector dose-dependent ( Figure 4a ). Further increases in vector dose (Ͼ0.6 × 10 9 p.f.u.) did not seem to signifiinto the adenoviral genome. To verify transgene transcription and protein release, 293 cells were infected with cantly enhance circulating IL-10 levels. Upon injection with 0.3 × 10 9 p.f.u., significant serum levels of mIL-10 10 p.f.u. per cell of Ad5E1mIL-10, total cellular RNA was extracted for Northern hybridization and supernatants were noticed as early as 8 h after i.m. gene transfer, being maximal at 24 h and still detectable by about day 10 were collected for ELISA at 24 h. Strong mRNA expression and protein release for mIL-10 were detected (Figure 4b ). These levels of IL-10 did not elicit any signs of sickness including ruffled fur, diarrhea or death or only in cells infected with Ad5E1mIL-10 but not with control vector (Figure 2b ). Other cell types could also be induce acute phase reactions. No detectable levels of IL-10 were found in mice receiving Ad5dl70-3 control veceffectively infected with Ad5E1mIL-10 to release IL-10 for about 4 weeks in vitro. These data display the efficacy of tor.
To examine the compartmentalization of transgene mIL-10 expression in various cell types, driven by the CMV promoter contained in this vector.
expression following i.m. gene transfer, mIL-10 mRNA was examined in various organs at day 1 after gene transTo examine the inhibitory effect of transgene product mIL-10 on cytokine expression in vitro, mouse or rat fer. While no detectable mIL-10 mRNA was found in any tissues of mice receiving the control vector, only the peritoneal macrophages were stimulated with 2 g/ml of endotoxin in the presence of supernatants generated muscle but not the lung, spleen, liver, heart or kidney from mice receiving Ad5E1mIL-10 i.m., expressed a from Ad5E1mIL-10-infected human lung fibroblasts (containing about 1 U mIL-10/l), or recombinant strong message for mIL-10 ( Figure 4c ).
To investigate the possibility of repeatedly adminismurine IL-10 as a positive control. Supernatants were then collected at 18 h after endotoxin challenge and tering Ad5E1mIL-10 at the same muscle sites, mice were given i.m. injections with the vector three times, 5 days examined for TNF␣ content by ELISA. As shown in Figure 3a and b, similar to recombinant mIL-10, apart and sera were collected at days 1 and 5 for IL-10 assay following each administration. Significant increases supernatants from fibroblast cultures infected with Ad5E1mIL-10 but not with the control vector, markedly in circulating IL-10 content were detected following the first and the second but not the third administration of inhibited TNF␣ production by both mouse and rat peritoneal macrophages, indicating that the transgene mIL-10 Ad5E1mIL-10 ( Figure 5 ), suggesting that it is possible to repeat intramuscular administration of the vector once protein was bioactive on both murine and rat cells.
within this time-frame if the maintenance of relatively high systemic levels of IL-10 is desired. Intramuscular gene transfer with Ad5E1mIL-10 Since intramuscular administration may represent a less Intramuscular mIL-10 gene transfer inhibits cytokine invasive and more accessible route for delivering IL-10 release and mRNA expression in endotoxemia transgene for potential therapeutic objectives, Ad5E1mIL-To examine the therapeutic potential of adenoviral vector expressing IL-10, 0.3 × 10 9 p.f.u. of Ad5E1mIL-10 was injected i.m. into each mouse and mice were challenged quickly but both peak around 1.5 h after endotoxin challenge. 20 Concentrations of TNF␣ and IL-6 were signifii.p. with a sublethal dose of endotoxin (150 g per mouse) 24 h after gene transfer. Pro-inflammatory cytocantly reduced only in mice expressing mIL-10 but not in mice receiving i.m. injection of PBS or the control vector kines TNF␣ and IL-6 were measured in sera collected at 1.5 h after endotoxin challenge. It has been well docu- (Figure 6a and b) . To examine the effectiveness of circulating IL-10 at different tissue sites, expression of TNF␣ mented that TNF␣ and IL-6 responses rise and fall and IL-6 mRNA was also analyzed in the lung, spleen, adenoviral vector expressing IL-10 may also become an invaluable tool in other in vivo therapeutic and functional liver, heart, kidney, thymus and hind leg muscle from these animals. Without endotoxin stimulation, these studies including those aiming to target IL-10 transgene to a specific tissue site. tissues expressed minimal mRNA for TNF␣ or IL-6, whereas endotoxin given i.p. markedly induced TNF␣ Following intramuscular delivery of the vector, the transgene mRNA for IL-10 was found only in the muscle mRNA expression in the lung, spleen and to a lesser degree, heart, and IL-6 mRNA in the lung, spleen, heart around injection sites but not in other tissues, giving rise to significant release of IL-10 into circulation. Confineand muscle, in mice receiving the control vector ( Figure  7 ). In contrast, TNF␣ mRNA expression in the lung and ment in the muscle of adenoviral vector after i.m. injection was also previously demonstrated by examining the spleen, and IL-6 mRNA in the lung and heart, were markedly reduced in mice expressing mIL-10 with maxitransgene promoter sequences by PCR. 23 Thus, intramuscular injection, as compared to i.p. or i.v., represents a mal inhibition seen in the lung (Figure 7) .
noninvasive, safe and more convenient way of achieving systemic distribution of IL-10 gene product since it only Adverse effects of high IL-10 concentration after intraperitoneal gene transfer involves a small and easily accessible cell population 23 and the viral infection is highly contained around the site In order to provide experimental data on the safety of IL-10 or IL-10 genetic vector usage, we asked whether too of injection, distant from the tissue sites where the effect of IL-10 is desired. In addition, this gene transfer-based much circulating IL-10 may bring about side-effects or toxicity by using Ad5E1mIL-10. To approach this, an i.p.
approach confers a much more prolonged circulating level of IL-10 than the use of recombinant IL-10. For gene transfer was used to achieve high systemic levels of IL-10. We and others have previously shown that by this instance, only 6.27 and 0.8 ng/ml serum of IL-10 were measured at 3 and 6 h, respectively, following i.v. injecapproach, the transgene carried in adenoviral vectors can be highly efficiently targeted to both peritoneal lining tion of 10 g/kg of recombinant IL-10 in humans.
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Sepsis or endotoxemia is a critical condition accounting mesothelial cells and macrophages and is compartmentalized within the peritoneal cavity, resulting in for significant morbidity and mortality. 24 The quick rise and fall of circulating cytokines is one of the major events efficient transgene protein release into the bloodstream.
13,21,22 Production of IL-10 after i.p. gene transfer occurring during endotoxemia. 24 Among all cytokines induced, TNF␣ and IL-6 represent two with the earliest was vector dose-dependent (data not shown). Using a dose of 0.6 × 10 9 p.f.u., a much higher peak serum level appearance. 20 ,24 TNF␣ appears to be a central player in endotoxemia-related lethality whereas IL-6 is a major of IL-10, as compared to that induced by i.m. delivery of the same dose of the vector, was achieved ( Table 1) . The contributor to a battery of metabolic changes including weight loss and acute phase reactions seen during endomice having these high concentrations of IL-10 developed an acute pathologic syndrome around 24 h, manifested toxemia. 24, 25 Despite recent progress in understanding the basic mechanisms underlying this condition, there is a by ruffled fur, diarrhea and occasionally death which were never observed in mice receiving the same or even lack of efficient therapeutic interventions. Recombinant IL-10 or IL-10-expressing plasmid has recently been higher doses of control vector. These signs of sickness were transient in nature in the majority of mice that surtested in endotoxic models to reduce TNF␣ and TNF␣-mediated effects. 2, 12 In our current study, we investigated vived. Death was invariably associated with pulmonary and/or cerebral bleeding. Histologically, diffuse the potential usefulness of an adenoviral vector expressing IL-10 for attenuation of both TNF␣ and IL-6 in endohemorrhage was seen in cerebral parenchyma and ventricles and in the pulmonary parenchyma and airways toxemia. By examining mRNA expression, different organs appeared to contribute differently to the surge of with hemorrhagic necrosis in some areas but with little evidence of inflammatory infiltration (Figure 8a and b) . cytokines in circulation upon endotoxin challenge, with spleen, lung and heart, or spleen, lung, heart and muscle, The intravascular thrombi and epithelial necrosis in the small intestine were sometimes observed in severely being major sites for TNF␣ or IL-6 expression, respectively. These cytokine responses were markedly attenuaffected mice (Figure 8c and d) . In contrast, little microscopic pathology was identified in other tissues. We next ated in mice receiving IL-10-expressing viral vector. We found that while cytokine mRNA expression was examined some parameters reflecting acute phase reaction. The level of IL-6 or acute phase protein ␣ 1 acid glyinhibited to varying degrees in different organs, the lung responded most vigorously to IL-10 action. These data coprotein (␣ 1 AGP) in serum was significantly elevated in association only with very high levels of IL-10 ( Table 2 ).
indicate that elevated systemic IL-10 levels following i.m. gene delivery are effective in reaching tissue sites to In contrast, TNF␣ was not detectable in any cases ( Table  2 ). The signs of sickness and elevated levels of acute execute biologic activities. Since sepsis-related death is frequently associated with the development of acute lung phase reactants waned as the level of IL-10 decreased.
injury and respiratory distress syndrome, our findings strongly propose the value of achieving systemic IL-10
Discussion delivery for superior protection to the lung from endotoxic injury while dampening the systemic cytokine IL-10 has shown great promise in treating a number of inflammatory and immune diseases including allergy response.
In addition to anti-inflammatory effects of IL-10 in vivo, and transplant rejection and IL-10 gene therapy for these conditions may represent one of more efficient therawe also demonstrated that IL-10 by itself when present in a wide range of concentrations after i.m. gene transfer, peutic regimens. Our studies provided and explored the rationale for using adenoviral vector as an IL-10 genewas nontoxic and nonproinflammatory, thus conforming to its general properties. 1 Since the potential toxic effects delivering vehicle in vivo. In addition to the therapeutic application in endotoxemia as we have shown here, the of IL-10 when present at very high levels, have not been adequately studied in vivo and there is a lack of infor-IL-10 production accompanied by increased acute phase proteins. These findings further confirm the antimation from the genetic transgenic model for IL-10 despite recent reports on the use of recombinant IL-10 in inflammatory nature of IL-10 and support the previous in vitro observation that IL-10 directly induces IL-6 by human phase I studies, 9,26 we investigated whether too much IL-10 could be toxic by efficiently transferring the endothelial cells. 28 They also provide the mechanism explaining why high doses of recombinant IL-10 caused IL-10 gene to the peritoneal cavity of mice. Our data indicate that the signs of sickness and intestinal pathology a flu-like syndrome in human volunteers. 26 The ability of high levels of IL-10 to induce IL-6, in contrast to its ability observed in mice were always associated with peak overproduction of IL-10, yet were transient in nature unless to inhibit IL-6 production during endotoxemia when present in lower amounts, suggests that the toxic effects there was lethal hemorrhage in the lung and/or brain. Nevertheless, high levels of systemic IL-10 after i.p. gene of a cytokine may be different from its biologic activities. The complexity of IL-10 effects in vivo is further exemtransfer do not seem to induce any overt inflammatory responses in tissues, similar to the case of i.m. gene transplified by the fact that while IL-10 has been shown to be anti-inflammatory and immunosuppressive, it may be fer. This is in sharp contrast to the effects of numerous other overexpressed proinflammatory cytokines in vivo. 27 proinflammatory or immunostimulatory under certain conditions. 7,29,30 The ability of extremely high systemic Upon examination of inflammatory cytokines in serum, only IL-6 but not TNF␣ was increased at the peak time of levels of IL-10 to induce acute phase responses and 
Materials and methods
Construction of recombinant adenoviral vector expressing mIL-10 A 1050 bp fragment of murine IL-10 (mIL-10) cDNA was excised from pCDSR␣ (obtained from DNAX Research Institute, Palo Alto, CA, USA) by BamHI and HindIII digestion. The shuttle plasmid pACCMV containing 0 to 17 map units (mu) human type 5 adenovirus genome with a human CMV promoter (760 bp), multicloning sites and SV40 splicing junction/polyA signal (430 bp) inserted in the E1 region of viral genome, was doubledigested with BamHI and HindIII. The IL-10 fragment was then subcloned into the BamHI-HindIII site in pACCMV using T4 ligase to obtain the recombinant plasmid PACCMVmIL-10 ( Figure 1 ). This plasmid was cotransfected into 293 cells along with a plasmid pAdBHG10 containing most of the rightward sequences (3.7 to 100 mu) of human type 5 adenovirus genome with Ad5dl70-3 or Ad5Lac, used as a control throughout the study, has previously been constructed and characterized. High titers of recombinant adenoviruses were amplified, purified, titered and stored as previously hemostatic disturbances certainly deserves further attendescribed.
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tion and holds the important implication in directing IL-10 gene therapy or therapies involving the use of recombinant IL-10. It also points to the potential mechanisms Characterization of adenovirus vector expressing mIL-10 The genomic DNA extracted from purified Ad5E1mIL-10 underlying the association of abnormally high levels of IL-10 with the deterioration of certain clinical was digested with HindIII and the fragments were analyzed by gel electrophoresis and Southern hybridization. conditions. 31 Thus, we have demonstrated the feasibility of using a Cell types including 293 cells, human alveolar epithelial A549 cells, human and rat primary lung fibroblasts, and replication-deficient adenoviral vector for delivering IL-10 transgene to tissue sites to achieve therapeutic effects freshly isolated rat alveolar macrophages, were infected with Ad5E1mIL-10 (10-20 p.f.u. per cell). Supernatants and the use of these vectors in examining toxicological aspects of IL-10 gene product. Currently, we are collected at different times after gene transfer were assayed for mIL-10 using an ELISA kit specific for mouse investigating the therapeutic applications of this vector in animal models for antigen sensitization, airway allergic IL-10 with the sensitivity of 15 pg/ml (Genzyme, Cambridge, MA, USA). In some instances, total cellular response, transplantation, tumor and fibrosis. Ad5E1mIL-10 (0.6 × 10 9 p.f.u.) was injected i.p. into mice and sera were collected at different times and assayed for mIL-10 by ELISA. Results are expressed as means ± s.e.m. of three mice. The control vector resulted in undetectable levels of mIL-10 in serum. RNA was extracted and analyzed for transgene mRNA endotoxin (055:B5 E. coli derived; Sigma, St Louis, MO, expression by Northern hybridization.
USA) in the presence of supernatants from Ad5E1mIL-To examine the inhibitory effect of transgene protein 10-infected human lung fibroblasts or recombinant mIL-10 on endotoxin-induced cytokine response in vitro, murine IL-10 protein (Genzyme) for 18 h, and the superfreshly isolated peritoneal macrophages from Balb/c natants were assayed for TNF␣ content using an ELISA mice or Sprague-Dawley rats (Charles River Laborakit specific for both mouse and rat TNF␣ (Genzyme). tories, Ottawa, Canada) were isolated and exposed to Intramuscular or intraperitoneal gene transfer with
